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Receptors for C3  bind  ligand  and  generate  intracellular  signals that  lead to 
the engulfment of C3-coated particles. Recent experiments suggest that both the 
binding and the subsequent signal transduction activities of C3 receptors can be 
regulated. Cultured human monocytes (MO)  1 express receptors for C3b (CR1) 
and  C3bi (CR3) that  bind ligand-coated particles  but do not signal  the cell to 
initiate  phagocytosis.  After  stimulation  of the  MO  with  PMA  (1),  or  after 
interaction  of the MO with surfaces coated with fibronectin (Fn, reference 2), 
CR1 and CR3 readily generate signals leading to phagocytosis. Thus PMA and 
Fn regulate the signaling capacity of CR1  and CR3 in these cells. In polymor- 
phonuclear leukocytes, both the binding and the signaling activities are coordi- 
nately  regulated.  Brief (15  min)  stimulation  with  PMA  increases binding  and 
signaling  activities of CR 1 and  CR3,  but prolonged  (60  min)  incubation  with 
PMA eliminates both binding and signaling (3). Since the PMA-mediated decline 
in  the binding  capacity of CR1  and  CR3  is not accompanied by a  loss of cell 
surface  receptors,  it  appears  that  PMA  regulates  the  binding  and  signaling 
activities of existing cell surface receptors. 
In  this  report,  we show that  treatment  of human  monocytes and  MO with 
recombinant IFN-~, causes CR1 and CR3 to lose the ability to bind ligand. IFN- 
"),-treated cells express normal  levels of cell surface CRI and CR3 as measured 
with anti-receptor antibodies, and the inhibition  of ligand binding by CR 1 and 
CR3  is  reversed  in  minutes  by interaction  of the  phagocytes with  Fn-coated 
surfaces.  Therefore,  cultivation  with  IFN-~,  causes a  reversible  change  in  the 
nature  of these receptors,  which  prevents  them  from  interacting  with  ligand. 
Although Fn enables CR1 and CR3 on IFN-~'-treated MO to bind ligand, these 
receptors fail to promote phagocytosis (signaling).  For signaling to occur, IFN- 
y-treated cells require exposure to both Fn and PMA. PMA enables only signaling 
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but does not influence binding. These data indicate that the capacity of receptors 
to bind ligand and to initiate a response are independently regulated. 
Materials and  Methods 
Reagents.  PMA  and aprotinin  were obtained from Sigma Chemical  Co.,  St.  Louis, 
MO. Recombinant IFN-'y and IFN-a were a gift of Hoffman-LaRoche Inc., Nutley, NJ, 
and the mAb, B133.3 directed against IFN-3, (4), was a generous gift of Dr. B. Perussia, 
Wistar Institute, Philadelphia, PA. Levels of immunoreactive IFN-3' were measured by a 
sensitive RIA (Centocor  Inc.,  Malvern,  PA).  mAb  3D9  directed  against  CR1  (5),  was 
provided by Drs. J. Oshea and E. Brown,  National Institutes of Health, Bethesda,  MD; 
mAb LeuM5 against p150/95 (6) was provided by Dr. C. Y. Wang, Sloan Kettering, New 
York; and mAb TS 1/22 directed against LFA-1 (7) was provided by Dr. T. A. Springer, 
Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA. OKM 1 and OKM 10 
directed against CR3, and 3C10 directed against a  55 kD protein unique to monocytes 
and macrophages were as previously described (8, 9). Affinity-purified F(ab)~ fragments 
of goat anti-:mouse IgG were purchased from Boehringer Mannheim Diagnostics, Inc., 
Houston, TX. Immunoglobulins were radioiodinated to a sp act of 0.4-2 ×  107 cpm/gg 
by the "iodogen" procedure (10).  Biotin-N-hydroxysuccinimide ester was purchased from 
Bethesda  Research  Laboratories,  Bethesda,  MD  and  was  used  to  biotinylate  OKMI0 
according to the  manufacturers instructions.  Colloidal gold conjugated to streptavidin 
was a kind gift ofJanssen Pharmaceutica, Beerse, Belgium. 
Cells.  Human  monocytes were purified  from buffy coats on  Percoll  gradients  and 
were cultured  with  12.5%  human serum in Teflon beakers as previously described (1). 
MO were iodinated with lactoperoxidase, extracted with Triton X-100, precipitated with 
OKM 1 or TS 1/22, and separated on gels as previously described (8). Sheep erythrocytes 
(E) coated with C3b (EC3b), C3bi (EC3bi), or IgG (EIgG) were prepared as described (1). 
The number of C3/E was determined  using iodinated  Fab fragments of a  monoclonal 
anti-C3, and the number of IgG/E was determined using directly iodinated IgG anti-E, as 
described previously (1). Unless otherwise stated, the EC3b, EC3bi, and EIgG were coated 
with ~80,000 ligands/sheep erythrocyte. 
Attachment  and  Phagocytosis of Ligand-coated  Erythrocytes.  Monolayers  of  MO  were 
prepared as follows. Cells were suspended at 0.75  ×  10~/ml in PBS (137 mM NaCl; 2.7 
mM KCI; 0.9  mM CaCI2; 0.5  mM  MgCI2; 8  mM phosphate, pH 7.4) containing  3 mM 
glucose,  0.5  mg/ml  human  serum  albumin  (HSA  [Worthington  Biochemical  Corp., 
Freehold, NJ]), and 0.3 U/ml aprotinin. Terasaki tissue culture plates (Miles Laboratories 
Inc., Naperville, IL) were coated with HSA (1 mg/ml), Fn (100 ~g/ml, Greater New York 
Blood  Center),  or OKM10  (50  ~g/ml) by a  60  min  incubation  at  20°C.  The culture 
surfaces were washed, 5 ul MO suspension was added per well, and cells were allowed to 
spread at 37°C for 45 rain. 
Attachment of ligand-coated E to monolayers of MO was determined by adding 5  × 
105 E/well and incubating for 45 min at 37°C.  The attachment of E to MO was scored 
by phase contrast microscopy as previously described (1).  Measurement of phagocytosis 
was made in a similar fashion and was scored after lysing uningested E by a brief exposure 
to distilled water. Results are reported as attachment index or phagocytic index, i.e., the 
number of E bound or phagocytosed per 100 phagocytes. 
Expression of Receptor Protein on the Cell Surface.  Monolayers of adherent MO prepared 
as described above were immersed in cold PBS without divalent cations (PD) containing 
1% FCS (PDFCS). Saturating amounts of mAbs (5 #g/ml) were then added to duplicate 
wells and the plates were incubated at 0°C for 50 rain. The monolayers were thoroughly 
washed and incubated with 5/~g/ml J25I-F(ab)2 anti-IgG for an additional 50 min at 0°C. 
After washing, individual wells were cut from the Terasaki plate and cell-bound radioac- 
tivity  was  counted  in  a  gamma counter.  Background  binding  was  measured  in  wells 
without primary antibody. Background binding varied from 75-150  cpm/well, and the 
binding to cells ranged from 1,500 cpm/well (3D9) to 20,000 cpm/well (OKM 10). Control 
experiments showed  that  MO  remained  attached  to the  culture  wells  throughout  the 
incubations. WRIGHT ET  AL.  1247 
Electron Microscopy.  Control of IFN-~,-treated MO  were  plated  on plastic surfaces 
coated  with  HSA  or  OKM10  for 60  min  at  37°C.  The  location  of CR3  was  then 
determined by  methods to  be  described  in  detail  elsewhere  (Detmers,  P.  A.,  et al., 
manuscript  in preparation).  In brief,  the cells were fixed in 0.2% glutaraldehyde,  1% 
ethyldimethylaminopropyl  carbodiimide (11), quenched with 0.5 mg/ml NaBH4 in PBS, 
and incubated sequentially with PDFCS, biotinylated OKM 10 (5 #g/ml in PD containing 
1 mg/ml HSA), and streptavidin-conjugated,  5-nm colloidal gold, with washes after the 
last two incubations.  Labeled cells were fixed in glutaraldehyde  and osmium tetroxide 
(12), dehydrated in a graded series of ethanol, and removed from the plastic surfaces by 
addition of propylene oxide (13). Monolayers pelleted by centrifugation in a microcentri- 
fuge were embedded in Epon, sectioned, stained with uranyl acetate and lead citrate, and 
viewed at 80 kV on a 100CX microscope (JEOL USA, Peabody, MA). Control prepara- 
tions included: (a) omission of biotinylated OKM10 and (b) addition of a 70-fold excess 
on nonbiotinylated  OKM 10 with the biotinylated OKM 10. No labeling with streptavidin 
gold was observed in either of these two cases (data not shown). 
Results 
IFN-,y  Decreases the  Capacity  of MO  To  Bind  C3b  and  C3bi-coated  Erythro- 
cytes.  IFN-'y (100  U/ml) was added at intervals to cultures of monocytes, and 
after 5 d the binding of EC3b and EC3bi to the MO was assessed. IFN-'y causes 
a sharp decline in binding of both EC3b and EC3bi, which is visible within 18 h 
and is maximal within 48 h  (Fig.  1). Addition of IFN-~, to MO  1 h before assay 
had no effect on binding (data not shown). The effect of IFN-~ does not result 
in a  generalized depression in the capacity of MO  to bind particles since the 
binding of EIgG is increased by treatment with IFN-"r (Fig. 1, references 14 and 
15). A depression in the binding of EC3b and EC3bi occurs when IFN-~, is added 
to freshly isolated monocytes or to 5-d cultures (data not shown), suggesting that 
responsiveness to IFN-~ is not developmentally regulated. A single dose of IFN- 
~, depresses binding of EC3b and EC3bi for 48 h, but receptor activity returns 
to normal levels after an additional 3 d  of culture (Fig.  i). We have found that 
MO deplete >90%  of the added IFN-~ within 48  h  (Table  I),  suggesting that 
reversal of the effects of IFN-'y may be caused by consumption of the added 
IFN-% This hypothesis is supported by the finding that the binding activity of 
CR1 and CR3 remains depressed in cultures to which fresh IFN--y was added at 
48  h  intervals (Fig.  1).  These observations suggest that the effect of IFN-~ on 
CR1 and CR3 is reversible and requires the continued presence of IFN-% 
Doses of IFN-"r as low as 25  U/ml cause a sharp decline in receptor activity, 
and maximal depression is observed at  100  U/ml  (Fig. 2).  This dose response 
range is comparable to that observed for IFN-'y-induced increases in Fc receptors 
(14),  Ia antigens (16,  17), and peroxide-producing capacity (18).  The action of 
our recombinant IFN-~ preparations derives from their IFN-T content, since a 
neutralizing monoclonal anti-IFN-~, antibody (4) completely blocks its action (Fig. 
2). Depression of the binding activity of CR1  and CR3 is not a property shared 
by all interferons since IFN-a had no effect on the binding of EC3b or EC3bi to 
MO (data not shown). 
The addition of IFN-'y to cultures of monocytes does not change the number 
of MO harvested after 2-5 d  (data not shown), suggesting that IFN-~, does not 
cause either cell proliferation or cell death. The entire population of monocytes 
appears to respond uniformly to IFN-~, since all cells in IFN-~-treated cultures 1248  BINDING ACTIVITY OF  COMPLEMENT  RECEPTORS  IS  REGULATED 
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FIGURE  1.  Attachment of ligand-coated  erythrocytes  to  monocytes  cultured for  various 
periods  with IFN-%  Monocytes were cultured for  120 h in RPMI  1640 containing 12.5% 
normal human serum.  At various times before the end of the cultivation,  I00 U/m] IFN-3, 
was added to the cultures.  The attachment of EC3b (O), EC3bi (n), or EIgG (X) was then 
measured as described in Materials and Methods. Monocytes given IFN-3, at the start of the 
culture period showed strong depression of the binding of EC3b and EC3bi after 48 h (data 
not shown), but during further cultivation for 3 d, the capacity to bind EC3b and EC3bi was 
recovered (O, II). MO consume >85 U/ml of IFN-3, within 48 h (Table I), and thus to maintain 
IFN-3' levels for extended periods, fresh IFN-3"  was added at 48 h intervals (O, r-l; 120 h time 
point). Results are representative of three separate experiments. 
TABLE  I 
Consumption of lFN-'r by MO 
Immunoreactive IFN-3, 
IFN-3, added  MO present  present after 48 h 
0  0  0.05  (+ 0.04) U/ml 
0  106/ml  0.42  (_ 0.38) U/ml 
100 U/ml  0  96  (- 22) U/ml 
I00 U/ml  106/ml  5  (_ 11.7) U/ml 
Identical cultures that contained 106 monocytes/ml  or medium alone were 
established. After cultivation  for 3 d, IFN-3' was added as shown, and after 
an additional 48 h of culture, the levels of immunoreactive IFN-q, in the 
cell-free culture supernatant was determined by RIA. The units of IFN-3, 
added were calculated from the antiviral titer of our rlFN-3' stock, and 
the units of immunoreactive  IFN-3, were calculated from parallel assays of 
standards supplied by Centocor Inc. Data represent the average of three 
experiments _+ SD. 
exhibited depressed binding of EC3b and EC3bi.  IFN-3,-treated MO  exhibit a 
highly uniform, round, well-spread appearance that  contrasts with  the  hetero- 
geneous  collection  of  spindle-shaped  and  irregularly  spread  cells  present  in 
untreated cultures (data not shown). WRIGHT  ET  AL.  1249 
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FIGURE 2.  Attachment of ligand-coated erythrocytes to MO exposed to different doses of 
IFN-7. Monocytes were cultured for 3 d, then various doses of IFN-3, were added. After an 
additional 48 h of culture, the attachment of EC3b (O), EC3bi ([3), or EIgG (X) was measured. 
Results are averaged from three experiments, and error bars depict standard deviations. • 
and •  depict an experiment in which the IFN-? was incubated for 30 rain with a  1.5-fold 
excess of the neutralizing anti-IFN-3,  antibody, B 133.3 (4), before addition to the phagocytes. 
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FIGURE 3.  Effect of ligand density on the attachment of ligand-coated erythrocytes to control 
and IFN-?-treated  MO. Erythrocytes were coated with various numbers of C3bi (A) or C3b 
(B) as described in  Materials and  Methods.  The attachment  of these erythrocytes was then 
measured using MO cultured for 5  d  in the absence (O) or presence (X) of 100 U/ml IFN-? 
(added at 48 h interval). 
The  effect  of ligand  density  on  the  binding  of EC3b  and  EC3bi  to  IFN-3,- 
treated MO  was next measured.  E  were prepared  bearing different numbers  of 
C3b  or C3bi,  and  the attachment  of these  particles was  determined  using  MO 
cultured  for  5  d  in  the  presence  or absence  of IFN-3,  (Fig.  3).  Half-maximal 
binding of E  to control MO  was observed with about  38,000  C3b or C3bi/E.  In 1250  BINDING  ACTIVITY  OF  COMPLEMENT  RECEPTORS  IS  REGULATED 
TABLE II 
Expression of Antigens in IFN-3,-treated Phagocytes 
mAb  Antigen 
Expression (relative to untreated MO) 
Mean +_ SD  n *  Significance* 
OKM1  CR3  0.99 _+ 0.24  8 
OKM10  CR3  1.I2 ___ 0.23  4 
3D9  CR1  0.76 _ 0.21  7 
TS1/22  LFA-I  2.08 + 0.49  9 
LeuM5  p150,95  1.03 + 0.18  7 
9.3F10  HLA class II  2.05 +_ 0.62  5 
3C10  p55  0.55 + 0.19  5 
p < 0.001 
p < 0.005 
p < 0.001 
Monocytes  were cultured for 5 d in the presence or absence of 100 U/ml IFN- 
% The binding of mAbs to monolayers of MO was then measured as described 
in Materials and Methods. Antigen expression on IFN-3,-treated MO is pre- 
sented relative to expression on untreated MO. 
Number of experiments performed. 
Probability that expression on IFN-7'-treated MO is not altered, based on a t 
test of paired samples. 
contrast,  half-maximal  binding of EC3b or EC3bi  to  IFN-3,-treated  MO  could 
not  be  observed even  with  120,000  C3/E.  The  inhibition  of CR1  activity by 
IFN-3, appears more complete than CR3 since moderate binding of EC3bi (one 
third maximal) can be observed with very high levels of C3bi per E (Fig. 3). 
IFN-'y  Does  Not  Decrease  the  Number  or  Molecular  Weight  of  C3  Recep- 
tors.  Though treatment  of MO  with  IFN-3, sharply decreases the capacity of 
MO to bind EC3b and EC3bi, the number of C3b and C3bi receptors detected 
with monoclonal anti-receptor antibodies is not radically altered. IFN-q,-treated 
MO expressed normal levels of CR3 antigens as measured by two separate anti- 
CR3 antibodies (Table II), and expression of CR1  antigen was lowered by only 
25%.  To  observe whether  all  the  cells  in  the  population  respond  similarly  to 
IFN-3', we measured expression of CR3 using a  FACS. These studies showed a 
unimodal distribution of CR3  on both control and IFN-q,-treated cells (Fig.  4). 
The  antigens  detected  by our  mAbs  appear  to be intact  receptors since  CR3 
immunoprecipitated from 125I surface-labeled, I FN-3,-treated MO exhibited elec- 
trophoretic mobilities identical with those from untreated MO (Fig. 5). 
Effect of lFN-y on the Expression of Other Cell Surface Antigens.  The expression 
of several other MO antigens was measured on control and IFN-7-treated cells. 
LFA-1, p150,95, and CR3 are ~Jfll heterodimers composed of an a  chain that is 
unique and a/3 chain that is common to all three proteins (19, 8). The expression 
of p150,95  was  unaffected by IFN-~,  (Table II),  but expression of LFA-1  was 
increased approximately twofold (Table II and  Fig.  5).  Induction of LFA-1  by 
IFN-3, on  murine  macrophages  has  been  recently reported (20).  We also con- 
firmed the observations of several other investigators (16,  17) that the expression 
of Ia  antigens  is  increased  by  IFN-y.  The  expression  of 3C10,  a  marker  for 
monocytes and macrophages (9), is decreased approximately twofold by IFN-7. 
The Ligand-binding Activity of CR1 and CR3 in IFN-y-treated MO Is Restored by 
Fn.  When  IFN-7-treated MO  were allowed to spread for 45  min on surfaces 
coated with Fn, the binding activity of CR1  and CR3 was fully restored (Table WRIGHT  ET  AL.  1251 
Fluorescence 
FIGURE 4.  Expression of CR3 on control and IFN-'r-treated MO. Monocytes were cultured 
for 4 d, then 100 U/ml IFN-~, was added as indicated. After an additional 48 h of cuhure, the 
MO were washed and incubated at 0°C  for 60  min with 2 tzg]ml OKM1.  Cells were then 
washed,  incubated with fluoresceinated  F(ah)2 fragments of goat  anti-mouse  Ig  (Scandic, 
Vienna, Austria),  then washed again.  The  fluorescence of the cells was  measured with an 
Ortho Diagnostic Systems Inc. FAGS II flow cytometer (Raritan, N  J) using a linear fluorescence 
scale. 
III). This action of Fn was observed over a  wide range of doses of IFN-3' (25- 
200 U/ml) and times of incubation with IFN-3, (18-120 h). The binding of IFN- 
y-treated MO to Fn-coated surfaces did not alter the number of CR 1 or CR3 on 
the cell (Table  III).  Thus,  Fn enhances  the capacity of CR1  and CR3  to bind 
ligand through an alteration in the function of existing receptors, not by a change 
in the  number of cell-surface receptors.  Interestingly,  the  effect of Fn  on  the 
capacity of CR1 and CR3 to mediate binding could not be mimicked with PMA 
(Table III). 
To test whether the effect of Fn on the binding activity of CR1  and  CR3 is 
reversible,  IFN-3,-treated  MO were removed with  EDTA from  Fn-coated sur- 
faces (21) and were plated on fresh HSA- or Fn-coated surfaces. IFN-~'-treated 
MO removed from Fn lose the ability to bind EC3b and EC3bi when they are 
replated for 45 min on control HSA-coated substrates (Fig. 6). However, binding 
activity can  be restimulated  by plating  these  MO on fresh  Fn-coated surfaces. 
Thus,  activation  of the  binding  activity  of CR1  and  CR3  by  Fn  requires  its 
continuous presence and is fully reversible. 
Effect of IFN-3, on the Capacity of Receptors To Promote Phagocytosis.  Previous 
work had  shown  that  treatment  of MO with  PMA enables CRI  and  CR3  to 
promote phagocytosis (reference  1 and Table IV). In IFN-3,-treated  MO, how- 
ever, PMA stimulated  neither  binding (Table III) nor phagocytosis (Table IV) 
mediated by CR 1 or CR3. Spreading of IFN-y-treated cells on Fn-coated surfaces 
stimulated the capacity of CR1 and CR3 to bind ligand (Table III), but did not 
enable  these  receptors  to  promote phagocytosis (Table  IV).  Phagocytosis was 
only initiated  by CR1  and  CR3  when  IFN-3,-treated  MO were simultaneously 
treated with Fn and PMA (Table IV). This observation suggests that  PMA and 
Fn have distinct effects on CR1 and CR3; Fn enables binding and PMA enables 
signaling. 
We  have  also  observed  that  although  IFN-3,-treated  MO  bind  EIgG  more 
avidly  than  untreated  control  cells  (Figs.  1  and  2),  phagocytosis  of EIgG  is 1252  BINDING ACTIVITY OF  COMPLEMENT  RECEPTORS  IS  REGULATED 
FIGURE 5.  The molecular weight of CR3 is not altered by IFN-3'. Monocytes were cultured 
for 5 d in the absence (a and b) or presence (c and d) of 100 U/ml IFN-3,. Cells were then 
iodinated, extracted,  and immunoprecipitated  with anti-CR3 (OKMI, a and c) or anti-LFA-1 
(TS1/22, b and d) using protein  A-Sepharose.  IFN-3, causes increased expression of LFA-1, 
but does not change the molecular weight of either CR3 or LFA-1 a chains. The protein A 
used in the procedure also precipitates IgG heavy and light chains (/4 and L) that are adsorbed 
to the MO. IFN-',/causes a sharp increase in the amount of IgG adsorbed to the MO, probably 
through increased expression of Fc receptors. 
depressed  two- to  threefold  in  IFN-3,-treated cells (Table  IV).  The capacity of 
IFN-'r-treated MO  to phagocytose  EIgG is partially restored  by the  combined 
action of Fn and PMA (Table IV). 
IFN-'r  Does  Not  Alter  The  Mobility  of CR3.  In  murine  macrophages,  the 
signaling capacity of C3 receptors correlates with their mobility in the membrane; 
receptors  that  do  not  promote  phagocytosis  do  not  diffuse  to  the  substrate- 
attached domain of phagocytes spread on C3-coated surfaces (22, 23). To observe 
the mobility of CR3 on IFN-3,-treated MO, cells were plated on surfaces coated 
with monoclonal anti-CR3  (OKM 10).  Previous studies showed that the CR3 on 
untreated  MO  is  redistributed  by such  substrates  so  that  the  apical  surface  of 
MO  becomes  depleted  of receptors  (8).  The  distribution  of CR3  on  IFN-3,- 
treated MO could not be determined with a  rosette assay because these MO do 
not bind  EC3bi.  We therefore tagged receptors with biotinylated  OKM 10 and 
streptavidin-colloidal  gold  as  described  in  Materials  and  Methods,  and  used 
electron microscopy to determine the cellular distribution of CR3.  Fig. 7 b shows WRIGHT ET  AL. 
TABLE  III 
The Inactivity of Complement Receptors on IFN-7-treated MO Is Reversed by Fn 
1253 
MO  Surface 
Attachment index  Receptor expres- 
sion 
EC3b  EC3bi  EIgG  CR1  CR3 
Control  HSA  790  770  946  100  100 
IFN-3'  HSA  160  113  1,520  96  91 
Control  Fn  792  664  929  98  94 
IFN-~,  Fn  814  750  1,618  95  87 
IFN-'r + PMA*  HSA  87  86  1,040  ND  ND 
Monocytes were cultured for 5 d in the absence (control) or presence of 100 U/ml IFN-% Cells 
were then allowed to spread  for 45 rain on plastic culture surfaces derivatized  with HSA or Fn, 
and the attachment index of the indicated ligand-coated erythrocyte  was determined as described 
in Materials and Methods. Expression of cell surface receptors  were measured in parallel prepara- 
tions using quantitative binding of the  mAbs OKM1  and 3D9  as described  in Materials and 
Methods, and data are given as the percent of antigen expression in control cells spread on HSA- 
coated surfaces. The experiment shown here is representative of five separate experiments. 
* 30 ng/ml PMA was added during the spreading of cells on an HSA-coated surface. 
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FIGURE 6.  Activation of the binding  activity of CR1 and CR3 by Fn is reversible. Monocytes 
were cultured for 3 d, then 100 U/ml IFN-"/was added and cultivation was continued for 48 
h. The IFN-7-MO were allowed to spread for 45 rain at 37°C on surfaces coated with HSA 
or Fn, and their capacity to bind EC3b (open bars) and EC3bi (hatched bars) was measured 
(left panel). A parallel preparation of IFN-o,-treated MO spread on Fn was eluted from the 
Fn-coated surface with EDTA (22), washed, and replated on fresh HSA- or Fn-coated surfaces, 
and the binding  of EC3b and EC3bi was again measured. 
that IFN-3,-treated cells plated on HSA-coated surfaces express abundant  CR3 
on the apical surface. Thus, the dysfunction of CR3 in IFN-3,-treated cells is not 
caused  by  gross  redistribution of  receptors.  Cells  spread  on  OKM10-coated 
surfaces express little if any CR3 on the apical surface (Fig. 7, c and d), indicating 
that the receptors diffused to the substrate-attached portion of the cell and were 
trapped by OKM 10. Since the extent of down-modulation of CR3 is comparable 
in both control and IFN-3,-treated cells, we  believe that  IFN-3, does  not cause 
gross  alteration of the  mobility of CR3.  Finally, we  have observed  that  CR3 
exists in clusters on both the control and IFN-3,-treated MO. Further studies are 1254  BINDING  ACTIVITY  OF  COMPLEMENT  RECEPTORS  IS  REGULATED 
TABLE  IV 
Phagocytosis of Ligand-coated Erythrocytes in IFN-'y-treated  MO 
MO  Treatment 
Phagocytic Index 
EC3b  EC3bi  EIgG 
Control  --  16  59  410 
Control  FN*  206  232  478 
Control  PMA*  272  317  263 
Control  PMA +  Fn  0  205  209  259 
IFN-3,  --  4  37  167 
IFN-~,  Fn  39  67  222 
IFN-3,  PMA  39  63  188 
IFN-~'  PMA +  Fn  347  555  341 
Monocytes were  cultured for  5  d  in Teflon beakers.  Where indicated,  100 
U/ml IFN-7 was added 48 h before the experiment. Monolayers of phagocytes 
were prepared and the phagocytosis of the indicated ligand-coated erythrocyte 
was  measured  as  described  in  Materials  and  Methods.  Data  are  from  an 
experiment representative of three separate experiments. 
Phagocytosis  was  measured  using monolayers  of MO  spread  on  Fn-coated 
surfaces. 
30 ng/ml PMA was added during the incubation of MO with the ligand-coated 
erythrocytes. 
Phagocytosis was measured in the presence of 30 ng/ml PMA using MO spread 
on Fn-coated surfaces. 
underway to determine whether the size and spacing of the clusters are influenced 
by IFN-3'. 
Discussion 
Here  we  show  that  cultivation  of human  monocytes or  macrophages with 
recombinant IFN-'y causes a  striking decrease in the capacity of CR1  and CR3 
to bind particles coated with the corresponding ligand. The dysfunction of CR 1 
and CR3 induced by IFN-3' appears distinct from previously described dysfunc- 
tions of receptors in macrophages, in that binding of ligand is affected. Human 
and mouse macrophages possess complement receptors that fail to initiate phag- 
ocytosis (1, 22), but only IFN-7-treated MO express receptors that fail to bind 
ligand. 
The biochemical mechanisms by which the binding activity of CR1  and CR3 
are regulated by IFN-3,  are not clear. Reduced binding activity is not the result 
of irreversible modifications such as proteolysis since the molecular weight of 
CR3 is not altered (Fig. 5), and the dysfunction is rapidly reversed when the MO 
spread on surfaces coated with Fn (Table III). Reduced binding activity is also 
not associated with decreased mobility of the cell surface receptors since they 
continue to diffuse readily in IFN-3,-treated MO (Fig. 7). Finally, reduced binding 
activity is not associated with changes in  the number of cell surface receptor 
molecules since the number of CR1 and CR3 is unchanged by treatment of MO 
with IFN-3,  or with Fn (Tables II and III). We thus propose that depression of 
binding activity of CR 1 and CR3 by IFN-3, is caused by reversible conformational 
changes in the receptors. Such conformational changes could result from post- 
translational modifications such as phospborylation or methylation, or from the 
binding of an inhibitory subunit or an allosteric effector. ~
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Regulation  of ligand  binding  activity  has  been  observed  for  several  other 
receptors. The binding affinity of epidermal growth factor receptors is depressed 
in  cells  treated  with  platelet-derived  growth  factor  (24),  and  the  affinity  of 
receptors for/3-adrenergic ligands (25) and FMLP (26) can be depressed by prior 
treatment  of  cells  with  ligand  (homologous  desensitization)  or  with  several 
pharmacologic  agents.  Regulation  of  binding  activity  may  thus  represent  a 
general  mechanism  for  controlling  a  cell's  responsiveness  to  a  ligand.  The 
observation that receptors may exist in a  state incapable of binding ligand also 
indicates that rosette assays and other measures of ligand binding may be poor 
indicators of the presence or absence of receptors on a cell. 
Spreading of IFN-3,-treated MO on Fn-coated surfaces enables CR1 and CR3 
to  bind  ligand,  but  the  receptors  remain  incapable  of signaling phagocytosis 
(Tables  III and IV). Treatment of IFN-~'-treated  MO with PMA enables CR1 
and CR3 to generate signals for phagocytosis, but only if binding is also enabled 
by Fn (Table IV). These observations suggest that the two functions of comple- 
ment receptors,  binding of ligand and signaling of phagocytosis, may be con- 
trolled at separate points in IFN-3,-treated cells; control of binding is exerted by 
Fn and control of signaling by PMA. 
Our  observations show that  the capacity of IFN-3,-treated  MO  to bind C3- 
coated cells is under physiological regulation; binding does not occur until the 
cells receive an additional stimulus (Fn).  Control mechanisms similar to those 
observed with CR1  and CR3 could potentially regulate other cell-cell adhesion 
events, such as the interaction of cytolytic T  cells with targets, the interaction of 
activated  macrophages  with  tumor cells,  and  the  interaction  of T  cells  with 
accessory cells. Since several of such cell-cell adhesion events are mediated by 
LFA-1, and since LFA-1  is structurally homologous to CR3 (8,  19), we suggest 
that cell-cell adhesion events mediated by LFA-1  may be controlled by changes 
in the binding activity of LFA-1. 
In  contrast  with  the  observations  on  complement-coated erythrocytes,  the 
binding of EIgG is strongly enhanced in IFN-7-treated MO (Fig. 1 and 2). These 
data are consistent with the well-documented increase in the expression of a high 
affinity  FcR  caused  by  IFN-'y  (14,  15).  IFN-3,-treated  MO,  however,  show 
decreased capacity to phagocytose EIgG (Table IV). These data suggest that the 
high-affinity FcR may not efficiently promote phagocytosis. Consistent with this 
hypothesis are the observations that >70%  of the uptake of EIgG is inhibited 
when the  low-affinity FcR  is  removed from  MO  (27),  and  clearance  of IgG- 
coated erythrocytes is decreased 98% by antibodies against a low-affinity receptor 
(28).  These observations  suggest that phagocytosis of IgG-coated particles  by 
MO may be promoted primarily by a  low-affinity FcR, not by the high-affinity 
FcR induced by IFN-% 
Summary 
Cultivation of human monocytes with recombinant IFN-7 causes a  5-10-fold 
depression in their binding of EC3b or EC3bi. This effect is observed within 18 
h and is expressed for 5 d  in the presence of 100 U/ml IFN-3'. The capacity of 
IFN-3,-treated  phagocytes  to  bind  EC3b  and  EC3bi  is  fully  restored  if  the 
phagocytes are allowed to spread for 45 min on surfaces coated with Fn. IFN-~- WRIGHT ET  AL.  1257 
treated  cells  express  normal  levels of cell  surface  C3b  and  C3bi  receptors as 
measured with monoclonal anti-receptor antibodies, and spreading on Fn does 
not alter receptor number.  We  conclude that  cultivation with  IFN-~  causes a 
change in the nature of these receptors that prevents them from interacting with 
iigand. Immunoelectron microscopy shows that C3bi receptors are expressed on 
the  apical  surface  of the  IFN-3,-treated  MO  and  that  these  receptors  exhibit 
normal capacity to migrate in the plane of the membrane. Thus, the nature of 
the  change  caused  by  IFN-~/  is  not  related  to  changes  in  receptor  number, 
location, or mobility. While spreading of IFN-~,-treated cells on Fn enables C3 
receptors  to  bind  ligand,  it  does  not  enable  them  to  promote  phagocytosis. 
Treatment of cells with PMA alone does not affect binding or phagocytosis, but 
treatment of cells with both Fn and PMA enables cells to phagocytose EC3b and 
EC3bi.  These  data  indicate  that  the  binding  and  signaling  activities  of C3 
receptors are separately regulated. Fn enables receptors to bind ligand and PMA 
enables them to signal phagocytosis. 
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